Quantification of major urinary metabolites of PGE2 and PGD2 in cystic fibrosis: Correlation with disease severity

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 89, Issue 2-3, 2013, Pages 121-126

  Jabr, Suha ^a   Gartner, Silvia ^b   Milne, Ginger L ^c   Roca Ferrer, Jordi ^a   Casas, Josefina ^d   Moreno, Antonio ^b   Gelpí, Emilio ^e   Picado, César ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

^e INST D INVESTIGACIONS B   (Spain)

Author keywords

Arachidonic acid; Cyclooxygenase; Cystic fibrosis; Prostaglandins; Tetranor PGD M; Tetranor PGE M

Indexed keywords

ARACHIDONIC ACID; CREATININE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE;

ADULT; AGED; ARACHIDONIC ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PANCREAS INSUFFICIENCY; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPIROMETRY;

ARACHIDONIC ACID; CYCLOOXYGENASE; CYSTIC FIBROSIS; PROSTAGLANDINS; TETRANOR PGD-M; TETRANOR PGE-M;

ADOLESCENT; CHILD; CYSTIC FIBROSIS; DINOPROSTONE; FEMALE; HUMANS; MALE; PROSTAGLANDIN D2;

EID: 84880626898     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.06.001     Document Type: Article

References (37)

1. Lyczak J.B., Cannon C.L., Pier G.B. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 2002, 15:194-222.
2. Verhaeghe C., Delbecque K., de Leval L., Oury C., Bours V. Early inflammation in the airways of a cystic fibrosis foetus. J. Cystic Fibrosis 2007, 6:304-308.
3. Lucidi V., Ciabattoni G., Bella S., Barnes P.J., Montuschi P. Exhaled 8-isopostane and prostaglandin E2 in patients with stable and unstable cystic fibrosis. Free Radical Biol. Med. 2008, 45:913-919.
4. Eickmeier O., Huebner M., Hermmann E., et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine 2010, 50:152-157.
5. Hunter M.J., Treharne K.J., Winter A.K., Cassidy D.M., Land S., Mehta A. Expression of wild-type CFTR suppresses NF-K{green}B-driven inflammatory signalling. Plos One 2010, 5:7e11598.
6. Tsui L.C. The spectrum of cystic fibrosis mutations. Trends Genet. 1992, 8:392-398.
7. Ooi C.Y., Dorfman R., Cipolli M., et al. Type of CFRT mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 2011, 140:153-161.
8. Kristidis P., Bozon D., Corey M., et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am. J. Hum. Genet. 1992, 50:1178-1184.
9. Cleveland R.H., Zurakowski D., Slattery D., Colin A.A. Cystic fibrosis genotype and assessing rates of decline in pulmonary status. Radiology 2009, 253:813-821.
10. de Gracia J., Mata F., Alvarez A., et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax 2005, 60:558-563.
11. Lai H.J., Cheng Y., Cho H., Kosorok M.R., Farrel P.M. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am. J. Epidemiol. 2004, 159:537-546.
12. Smith W.L., Dewitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69:145-182.
13. Roca-Ferrer J., Pujols L., Gartner S., et al. Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax 2006, 61:592-596.
14. Zakrzewski J.T., Barnes N.C., Piper J., Costello J.F. Detection of sputum eicosanoids in cystic fibrosis and in normal saliva by bioassay and radioimmunoassay. Br. J. Clin. Pharmacol. 1987, 23:19-27.
15. Yang J., Eiserich J.P., Cross C.E., Morrisey B.M., Hammock B.C. Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. Free Radical Biol. Med. 2012, 53:160-171.
16. Strandvik B., Svensson E., Seyberth H.W. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins, Leukotrienes Essent. Fatty Acids 1996, 55:419-425.
17. Medjane S., Raymon B., Wu Y., Touqui L. Impact of CFTR {increment}F508 mutation on prostaglandin E2 production and type IIA phospholipase A2 expression by pulmonary epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289:L816-824.
18. Carlstedt-Duke J., Brönnegard K., Strandvik B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc. Natl. Acad. Sci. USA 1986, 83:9202-9206.
19. Chen J., Jiang X.H., Chen H., et al. CFRT negatively regulates cyclooxygenase-2-PGE2 positive feedback loop in inflammation. J. Cell Physiol. 2012, 227:2759-2766.
20. Hinz B., Brune K., Pahl A. Cyclooxygenase-2 expression in lipopolysacharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E2, and non steroidal anti-inflammatory drugs. Biochem. Biophys. Res. Commun. 2000, 278:790-796.
21. 2 induces COX-2 expression in podocytes via the EP4 receptor through a PK-independent mechanism. Cell Signalling 2008, 20:2156-2164.
22. Duffield-Lillico A.J., Boyle J.O., Zhou X.K., et al. Levels of prostaglandin E metabolite and leukotriene E (4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev. Res. 2009, 2:322-329.
23. Song W.L., Wang M., Ricciotti E., et al. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J. Biol. Chem. 2008, 283:1179-1180.
24. Alonso M.J., Heine-Suñer D., Calvo M., et al. Spectrum of mutations in the CFRT gene in cystic fibrosis patients of Spanish ancestry. Ann. Hum. Genet. 2006, 71:194-201.
25. 2 synthesis in healthy humans and those with lung cancer. Anal. Biochem. 2004, 334:266-275.
26. Que C., Cullinan P., Geddes D. Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax 2006, 61:155-157.
27. Clayton A., Holland E., Pang L., Knox A. Interleukin-1β differentially regulates β2 adrenoreceptor and prostaglandin E2-mediated cAMP accumulation and chloride efflux from Calu-3 bronchial epithelial cells. Role of receptor changes, adenylcyclase, cyclooxygenase 2, and protein kinase A. J. Biol. Chem. 2005, 280:23451-23463.
28. Korhonen R., Kosonen O., Korpela R., Moilenen E. The expression of COX-2 protein induced by Lactobacillus rhamnosus GG, endotoxin and lipoteichoid acid in T84 epithelial cells. Lett. Appl. Microbiol. 2004, 39:19-24.
29. Osika E., Cavaillon J.M., Chadelat K., et al. Distinct sputum cytokine profiles in cystic fibrosis and other inflammatory airway diseases. Eur. Res. J. 1999, 14:339-346.
30. Hurley B.P., Pirzai W., Mumy K.L., Gronert K., McCormick B.A. Selective eicosanoid-generating capacity of cytoplasmic phospholipase A2 in Pseudomonas aeruginosa-infected epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300:L286-L294.
31. Vancheri C., Mastruzzo C., Sortino M.A., Crimi N. The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol. 2004, 25:40-46.
32. 1 decline in children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2007, 176:1084-1089.
33. Li J., Xiang Y.Y., Ye L., Tsui L.C., MacDonald J.F., Hu J., Lu W.Y. Nonsteroidal anti-inflammatory drugs up-regulate function of wild-type and mutant CFTR. Eur. Respir. J. 2008, 32:334-343.
34. Walkowiak J., Sand D., Nowakowska A., et al. Early decline of pancreatic function in cystic fibrosis patients with Class 1 and Class 2 mutations. J. Pediatr. Gastroenterol. Nutr. 2005, 40:199-201.
35. Ooi C.Y., Durie P.R. Cystic fibrosis transmembrane conductance regulator (CFRT) gene mutations in pancreatitis. J. Cystic Fibrosis 2012, 11:355-362.
36. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000, 67:117-133.
37. Czerska K., Sobecynska-Tomaszewska A., Sands D., et al. Prostaglandin-endoperoxide synthase genes COX-1 and COX-2 novel modifiers of disease severity in cystic fibrosis patients. J. Appl. Genet. 2010, 51:323-330.